- About EAS
|Guidelines on management of dyslipidaemia 2016|
These updated 2016 guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. The guidance includes sections on: the evaluation of laboratory lipid and apolipoprotein parameters; treatment targets; lifestyle modifications to improve the plasma lipid profile; drugs for treatment of hypercholesterolaemia and hypertriglyceridaemia; drugs affecting HDL-cholesterol; managing dyslipidaemias in different clinical settings; monitoring lipids and enzymes in patients on lipid-lowering therapy; and strategies to encourage adoption of healthy lifestyle changes and lipid-modifying therapies.
Publication in full
01/02/2017 » 01/05/2017
Abstract submission for the 40th Annual Scientific ELC meeting opens!
08/06/2017 » 10/06/2017
EAS-endorsed event MSDA 2017, Saint-Petersburg